VitaSpring Biomedical Reports No Revenue, Increased Operating Expenses, and Ongoing Financial Challenges

VitaSpring Biomedical Co., Ltd. reported its financial results for the three and nine months ended October 31, 2025, revealing a continued lack of revenue generation. The company recorded no revenues during this period, consistent with the previous fiscal year. Operating expenses for the three months totaled $135,733, an increase from $117,927 in the same period last year. For the nine months, operating expenses decreased to $303,947 from $553,420, reflecting a significant reduction in costs. The net loss for the three months was $142,518, compared to a loss of $196,292 in the prior year, while the nine-month net loss improved to $333,904 from $631,785.

The balance sheet as of October 31, 2025, showed total assets of $16,465,000, an increase from $14,378,000 at the end of January 2025. Current liabilities rose to $4,365,569, up from $4,029,578, primarily due to increases in accounts payable and advances from related parties. The company’s accumulated deficit grew to $5,615,407, up from $5,281,503, indicating ongoing financial challenges. The cash position improved slightly to $1,960 from $272, but the company continues to face a working capital deficit of $4,355,742.

VitaSpring has not engaged in any significant acquisitions or product launches during this reporting period. The company remains focused on its core mission of developing stem cell applications in regenerative medicine, but it has not yet established active revenue-generating operations. The company’s operational metrics indicate a reliance on related-party financing, with advances from related parties totaling $1,002,338 as of October 31, 2025. The company has entered into a deferred payment agreement with a related party regarding accounts payable, which may provide temporary relief from immediate financial pressures.

Management has expressed concerns regarding the company's ability to continue as a going concern, citing minimal cash reserves and recurring operating losses. The company plans to seek additional capital through equity financing and strategic partnerships to fund operations and meet obligations. However, there is no assurance that such financing will be available on acceptable terms. The financial statements reflect a critical need for improved liquidity and operational viability as the company navigates its financial landscape.

Looking ahead, VitaSpring's management acknowledges the challenges posed by its current financial situation and the necessity for strategic decisions to enhance its operational capacity. The company aims to leverage its research and development capabilities in the stem cell sector, but the lack of revenue generation and reliance on related-party financing raises questions about its long-term sustainability. The outlook remains uncertain as the company continues to seek ways to stabilize its financial position and achieve its business objectives.